Successful Subcutaneous Immunoglobulin Therapy in a Case Series of Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
Sjogren, Per, Bragée, Bjorn, Britton, Sven · Clinical therapeutics · 2024 · DOI
Quick Summary
This study tested a treatment called subcutaneous immunoglobulin (a protein that helps the immune system) in 17 ME/CFS patients whose symptoms seemed to be triggered by infections. After 5 weeks of treatment, patients reported significant improvements in their symptoms, quality of life, and ability to work, with no serious side effects. One patient reported their ME/CFS symptoms disappeared completely.
Why It Matters
This research provides preliminary evidence that immunoglobulin therapy may benefit a specific subset of ME/CFS patients—those with infection-related symptomatology—which could represent a step toward precision medicine approaches in this understudied disease. The findings support further investigation into immune-based treatments and suggest that not all ME/CFS patients are homogeneous in their treatment response.
Observed Findings
Significant improvement in symptom severity after 5 weeks of treatment (P < 0.05)
Quality of life increased by a median of 35 points (on 0-100 scale) in the 7 highest responders
Working ability significantly improved with median increase from 5 to higher values (P < 0.05)
One patient reported complete elimination of ME/CFS symptoms
No serious adverse effects were detected during the treatment period
Inferred Conclusions
Low-dose subcutaneous immunoglobulin may produce pronounced beneficial effects in patients with infection-related ME/CFS
A subgroup of ME/CFS patients with recurrent infections may respond differently to immunologic treatment than other ME/CFS presentations
Further well-controlled clinical trials are warranted to determine the true efficacy and optimal use of immunoglobulin therapy in this patient population
Remaining Questions
Do the observed improvements persist beyond 5 weeks, and what is the optimal duration and dosing of immunoglobulin therapy?
How can clinicians reliably identify which ME/CFS patients have infection-driven disease and will likely respond to immunoglobulin treatment?
What This Study Does Not Prove
This case series does not prove that immunoglobulin is an effective ME/CFS treatment for all patients; it only suggests potential benefit in patients with infection-driven symptoms. Without a control group or blinding, improvements could be partially attributed to placebo effect or natural disease fluctuation. The short 5-week timeframe does not establish whether benefits persist long-term.